UNLIMITED TURBO SHORT - ELI LILLY & CO | Real-time Euronext Paris 05:39:27 28/05/2024 pm IST | ||
| 3.197 EUR | +1.91% |
|
| Current month | -19.87% | ||
| 1 month | -32.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 3.197 | +1.91% |
| 27/24/27 | 3.137 | -2.18% |
| 24/24/24 | 3.207 | +4.19% |
| 23/24/23 | 3.078 | -9.60% |
| 22/24/22 | 3.405 | +2.65% |
Real-time Euronext Paris
Last update May 28, 2024 at 05:39 pm IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| BC6NB | |
| ISIN | NLBNPNL2PF04 |
| Date issued | 25/03/2024 |
| Strike | 969.3 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.58 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.03 € |
|---|---|
| Lowest since issue | 3.046 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- BC6NB Certificat
